NCT05541822 2025-05-22
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Abion Inc
Phase 2 Recruiting
Abion Inc
Shanghai Hengrui Pharmaceutical Co., Ltd.
BeiGene
Shanghai Hengrui Pharmaceutical Co., Ltd.
Astellas Pharma Inc
PharmaMar
Antengene Corporation
Jiangsu HengRui Medicine Co., Ltd.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Jiangsu Simcere Pharmaceutical Co., Ltd.